Literature DB >> 1553101

Behavioural pharmacology of 5-HT3 receptor ligands.

J M Barnes1, N M Barnes, S J Cooper.   

Abstract

Extensive studies have ascribed a role for the central 5-HT3 receptor in the modulation of behaviour. Much of the work stems from the actions of potent and selective 5-HT3 receptor antagonists; these agents reduce mesolimbic dopamine initiated hyperactivity, release suppressed behaviour, reduce the reinforcing properties and withdrawal symptoms of drugs of abuse, enhance cognitive performance and modulate appetite. This article reviews the preclinical and clinical evidence implicating the 5-HT3 receptor in these indications and discusses the potential neurochemical mechanisms underlying the behavioural changes.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1553101     DOI： 10.1016/s0149-7634(05)80057-0

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN： 0149-7634            Impact factor:   8.989


  12 in total

Review 1.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Tardive dyskinesia: treatment with aripiprazole.

Authors:  Na-Ri Kang; Moon-Doo Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

3.  Lack of effects of 5-HT3 antagonists on normal and morphine-attenuated sexual behaviours in female and male rats.

Authors:  S A Tanco; N V Watson; B B Gorzalka
Journal:  Experientia       Date:  1993-03-15

4.  Nervous system distribution of the serotonin 5-HT3 receptor mRNA.

Authors:  L H Tecott; A V Maricq; D Julius
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

Review 5.  5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.

Authors:  J E Barrett; K E Vanover
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligands.

Authors:  J M Barnes; N M Barnes; B Costall; S M Jagger; R J Naylor; D W Robertson; S Y Roe
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

7.  Distribution of [3H]GR65630 binding in human brain postmortem.

Authors:  D Marazziti; L Betti; G Giannaccini; A Rossi; I Masala; S Baroni; G B Cassano; A Lucacchini
Journal:  Neurochem Res       Date:  2001-03       Impact factor: 3.996

8.  The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.

Authors:  I Artaiz; G Romero; A Zazpe; A Monge; J M Calderó; J Roca; B Lasheras; J Del Río
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

9.  Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.

Authors:  N M Barnes; C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

10.  Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron.

Authors:  L J Steward; J Ge; K R Bentley; P C Barber; A G Hope; J J Lambert; J A Peters; T P Blackburn; N M Barnes
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.